Is cell-free the future of vaccine development?

As the world emerges from the COVID-19 pandemic, the focus on rapid and effective vaccine development to address new and re-emerging diseases has never been stronger. Virus-like particles (VLPs) show promise as an alternative to traditional vaccine platforms as they trigger a strong and lasting immune response, with fewer safety concerns and higher stability than existing vaccine technologies.

In this 30 minute webinar, our speaker, Jorge Armero Gimenez, will present his work on expression and assembly of immunogenic VLPs using a high-yielding cell-free protein synthesis system at scales useful to vaccine development.

What is the main reason for your interest in this webinar?
Are you currently working with VLPs?

Speaker Bio


Jorge Armero GimenezResearch and Development - System Innovation

Jorge Armero Gimenez Research and Development – System Innovation

Jorge Armero Gimenez is a doctoral student at the Department of Plant Sciences at Wageningen University & Research (WUR). He is co-supervised within the Research and Development department of LenioBio GmbH. His research is focused on developing a versatile and rapid vaccine development platform for new or re-emerging diseases. Through his research, Jorge has become an expert user of LenioBio’s ALiCE protein expression technology. Prior to his PhD studies, Jorge was awarded a Master in Plant Biotechnology with a cum laude distinction at WUR.

The technology behind the talk

Our cell-free protein expression kits contain our Almost Living Cell-Free Expression (ALiCE®) technology. ALiCE® is a lysate derived from eukaryotic cells and contains all of the protein expression machinery needed to produce even the most complex proteins, including those requiring post-translational modifications.

InBev_ProductionLine_FREE-1920w (1)

No results